Skip to content

Outcomes of Natives and Graft-related Femoral Reconstruction With Tubulized Pericardial Patchs

Early Outcomes of Natives and Graft-related Femoral Reconstruction Managed With Orthotopic Xenopericardial Patchs

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05881954
Enrollment
20
Registered
2023-05-31
Start date
2020-01-01
Completion date
2023-09-01
Last updated
2023-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Complications

Brief summary

Groin wound infection after arterial femoral prosthetic reconstruction or percutaneous access and drug abusers are frequent and increase largely the post operative morbi-mortality. There is no perfect substitute to replace infected graft or to restaure femoral artery in septic condition moreover when all the femoral bifurcation is involved with a femoro-femoral bypass mandatory. Seeing the encouraging results of rolled pericardium patch to treat native and prosthetics aortic infections in term of patency and infection resistance, the investigators propose to evaluate the outcomes of this subsitute rolled with samples in case of femoro-femoral repair in septic condition.

Detailed description

Groin wound infection after vascular surgery is a frequent complication with a significant increase in post operative morbidity and mortality. Actual studies reported more than 20% of patients who develop groin wound infection with an important rate of reintervention and risk in limb loss. Theses groin complications are frequent in drug abusers but can also happen after percutaneous femoral access for endovascular therapy leading to arterial reconstruction. After mechanical debridement and eventually muscle flap rotation, ESVS 2020 guidelines recommend in situ reconstruction with the use of autogenous reconstruction vein femoral vein but it is a demanding surgery especially in redo surgery with extensive incision and deep venous complication. Saphenous vein is often too small in diameter to perform a femoro-femoral reconstruction. The other possibility is cryopreserved Cadaveric Arterial Allograft which are difficult to obtain in sufficient time for an urgent operation with frequent aneurysmal evolution. Literature reports up to 30% of reinfection with rifampin-soaked Dacron conduit are used with frequent reintervention. Rolled Bovine pericardium grafts have been proposed as a primary intention substitute in native and prosthetics aortic infections and are presented as resistant to infection when used as patch repair in case of groin complications. The aim of our study was to evaluate the outcomes in term of patency, limb salvage and infection resistance of this substitute when tubulized with stample in groin wound infection to replace previous prosthetic graft with active infection or false aneurysm rupture or after percutaneous septic femoral access complication in emergency surgery.

Interventions

PROCEDUREGroin infection

Femoral artery reconstruction with tubulized pericardium patch

Sponsors

University Paul Sabatier of Toulouse
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Previous femoral artery reconstruction with infected graft * Femoral artery septic false aneurysm needed complete arterial reconstruction (drug abuser or percutaneous femoral access)

Exclusion criteria

* Simple patch closure of femoral artery * Groin infection without femoral artery reconstruction Pregnancy Minors

Design outcomes

Primary

MeasureTime frameDescription
Patency3 monthsPatency of the bypass
Absence of reinfectionAfter antibiotherapy (6 weeks generally)Disparition of infections signs : biological and clinically

Secondary

MeasureTime frameDescription
Reintervention30 days post operative; 3 months, 6 months, 12 monthsNeed of reoperation during the follow up
Late patency6 monthsPatency of the Bypass

Countries

France

Contacts

Primary ContactAurélien H [ahostalrich]
hostalrich.a@chu-toulouse.fr0673303969

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026